Royalty Pharma has acquired rights to Amgen’s Imdelltra (tarlatamab-dlle), an FDA-accelerated approval immunotherapy for extensive-stage small cell lung cancer (ES-SCLC), in a deal valued up to $950 million. Imdelltra acts as a bispecific T-cell engager, activating the immune system to kill cancer cells, with sales exceeding $215 million in its first half-year on market. BeOne Medicines retains exclusive rights for distribution in China. This acquisition underscores strong commercial growth potential in the aggressive ES-SCLC segment affecting over 200,000 US patients annually.